circadian clock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
In 2021, Schmitt led a lawsuit against the Biden administration challenging COVID-19 vaccine requirements for health care workers. In 2021, Schmitt challenged the administration's decision to suspend new oil and gas leases on federal land and water. In 2021, Schmitt and 13 other Republican state attorneys general sued to block an executive order directing federal agencies to consider the social costs of emissions of greenhouse gases (carbon, methane and nitrous oxide) in regulatory cost-benefit analyses. In 2021, Schmitt and 21 other Republican attorneys general sued the Biden administration over Biden's revocation of the permit for the Keystone XL Pipeline. In 2022, Schmitt and Jeff Landry of Louisiana sued the federal government, claiming it was censoring anti-vaccine activism on social media. In 2024, the Supreme Court in Murthy v. Missouri rejected the case due to the plaintiffs' lack of standing. In the decision, Justice Amy Coney Barrett found no evidence of government coercion and wrote that plaintiffs could not "manufacture standing" based on hypothetical or self-inflicted harm. In 2022, Schmitt and 21 other Republican state attorneys general sued the Biden administration over a program that prohibits discrimination based on sexual orientation and gender identity in schools that receive federal funds. In September 2022, Schmitt joined a lawsuit on behalf of the Higher Education Loan Authority of the State of Missouri to block the administration's executive order on student debt relief.
Sulfadimidine or sulfamethazine is a sulfonamide antibacterial. There are non-standardizeda abbreviations for it as "sulfadimidine" (abbreviated SDI and more commonly but less reliablyb SDD) and as "sulfamethazine" (abbreviated SMT and more commonly but less reliablyc SMZ). Other names include sulfadimerazine, sulfadimezine, and sulphadimethylpyrimidine.
CpG site Also CG site and C-G site. A sequence of DNA in which a cytosine nucleotide is immediately followed by a guanine nucleotide on the same strand in the 5'-to-3' direction; the "p" in CpG refers simply to the intervening phosphate group linking the two consecutive nucleotides.
In multicellular organisms with dedicated reproductive cells, mutations can be subdivided into germline mutations, which can be passed on to descendants through their reproductive cells, and somatic mutations (also called acquired mutations), which involve cells outside the dedicated reproductive group and which are not usually transmitted to descendants. Diploid organisms (e.g., humans) contain two copies of each gene—a paternal and a maternal allele. Based on the occurrence of mutation on each chromosome, we may classify mutations into three types. A wild type or homozygous non-mutated organism is one in which neither allele is mutated.
Sources: en.wikipedia.org
Platelet-derived growth factor receptor (PDGFR) Epidermal growth factor receptor (EGFR) Insulin receptor and insulin-like growth factor 1 receptor (IGF1R) Stem cell factor (SCF) receptor (also called c-kit, see the article on gastrointestinal stromal tumor).
Trump stated that if he were elected, he would increase deportations, send the U.S. military to the border, expand U.S. Immigration and Customs Enforcement detentions through workplace raids, deputize local law enforcement to handle border security, increase U.S. Customs and Border Protection funding, as well as finish building the wall on the southern border. Trump has said he will deport both legal and illegal immigrants. The New York Times reported that Trump was considering "an extreme expansion of his first-term crackdown on immigration", such as "preparing to round up undocumented people already in the United States on a vast scale and detain them in sprawling camps while they wait to be expelled". Trump stated his intention to deport 11 million people through the construction of detention camps and deploy the military, relying on presidential wartime powers under the 18th-century Alien Enemies Act. Trump made false claims of a "migrant crime wave" that are not supported by data, and provided no evidence to back up his claims. In regards to his anti-immigrant nativism, Trump's tone grew harsher from his previous time as president, and used fearmongering, racial stereotypes, and more dehumanizing rhetoric when referring to illegal immigrants.
PLA does not publish detailed gender composition of its armed forces, but the Jamestown Foundation estimated approximately 5% of the active military force in China is female. National unity and territorial integrity are central themes of the Chinese Communist Revolution. The Chinese Red Army and the succeeding PLA actively recruited ethnic minorities. During the Chinese Civil War, Mongol cavalry units were formed. During the Korean War, as many as 50,000 ethnic Koreans in China volunteered to join the PLA. PLA's recruitment of minorities generally correlates to state policies. During the early years, minorities were given preferential treatment, with special attention given to recruitment and training. In the 1950s, ethnic Mongols accounted for 52% of all officers in Inner Mongolia military region. During the Great Leap Forward and Cultural Revolution, armed forces emphasized "socialist culture", assimilation policies, and the construction of common identities between soldiers of different ethnicities. For ethnic minority cadets and officials, overall development follows national policies. Typically, minority officers hold officer positions in their home regions. Examples included over 34% of the battalion and regimental cadres in Yi autonomous region militia were of the Yi ethnicity, and 45% of the militia cadres in Tibetan local militia were of Tibetan ethnicity. Ethnical minorities achieved high-ranking positions in the PLA, and the percentage of appointments appears to follow the ratio of the Chinese population composition.
Sources: en.wikipedia.org
=== Other lawsuits, investigations, and prosecutions === In August 2019, Schmitt withdrew a legal brief that argued that the First Amendment allowed government officials to withhold records from a freedom of information request, following criticism from transparency advocates who noted that the brief did not cite any case law. A Freedom Center of Missouri representative raised concern that the argument is similar to a case involving Governor Mike Parson, which Schmitt had not yet ruled on. Under Schmitt, the attorney general's office sued the city of Marshfield, Missouri, alleging that it maintained a ticket-quota system, in violation of the state law Schmitt had sponsored as state senator banning such quotas. In 2020, the suit ended in a settlement in which the city agreed to maintain a compliance program and have its state officials undergo training on the law. In September 2019, a bipartisan group of state attorneys general, including Schmitt, launched an antitrust investigation against Google. The attorneys general accused Google of prioritizing searches for companies that advertise on the search engine platform in violation of antitrust law.
PSGAG inhibits the synthesis of prostaglandin E2, which is released upon joint injury and causes inflammation, increases the loss of proteoglycan, and reduces the threshold of pain receptors. Inhibiting the complement pathway further reduces inflammation, most likely by altering C-reactive protein. The inhibition of blood coagulation reduces resultant fibrinolysis, which would cause cell death and increase local inflammation. PSGAG also stimulates the synthesis of glycosaminoglycans, hyaluronic acid, and collagen, which increase synovial viscosity. It cannot, however, completely reverse the disappearance of cartilage, nor can it reverse bone loss caused by arthritis.
Action Half-Life is a mod for the first-person shooter video game Half-Life. It strives to simulate action movies, especially those directed by John Woo. Action Half-Life is the second mod in the "Action" series. The first was Action Quake 2 and the third was Action Unreal Tournament 2004.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.